Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1438 • ACR Convergence 2022
The Ratio Between Biological and Glucocorticoid Use in Different Countries Worldwide: Results from the METEOR Registry
Isabell Nevins¹, CF Allaart¹, David Vega Morales², Lai Ling Winchow³, Arvind Chopra⁴, Ana Maria Rodrigues⁵, Tom Huizinga¹, Maarten Boers⁶ and Sytske Anne Bergstra⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Autonomous University of Nuevo León, Monterrey, Mexico, ³Chris hani baragwanath academic hospital, Johannesburg, South Africa, ⁴Center for Rheumatic Diseases, Pune, Maharashtra, India, ⁵Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, ⁶Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁷LUMC, Leiden, Netherlands
Background/Purpose: Previous studies have demonstrated differing bDMARD prescription rates between countries, which seems to be amongst others related to a country's socioeconomic status. In contrast,…
Abstract Number: 1638 • ACR Convergence 2022
Epidemiology of Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease in the Veterans Health Administration from 2004 to 2018
Benjamin Fletcher¹, Punyasha Roul², Yangyuna Yang³, Brian Sauer⁴, Jorge Rojas⁵, Grant Cannon⁶, Joshua Baker⁷, Ted Mikuls⁸ and Bryant England³, ¹University of Nebraska Medical Center, Omaha, ²UNMC, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁶Salt Lake City VA, Salt Lake city, ⁷University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Epidemiologic studies estimating RA prevalence and incidence have primarily been conducted in populations where the majority of RA patients are women. Because of phenotypic…
Abstract Number: 1739 • ACR Convergence 2022
Single-Cell Characterization of the TCR Repertoire Across Tissue and Blood in Rheumatoid Arthritis
Garrett Dunlap¹, Aaron Wagner², Nida Meednu³, Anna Jonsson⁴, Fan Zhang⁵, Kevin Wei⁶, Paul Utz⁷, William Robinson⁷, Holden Maecker⁷, Judith James⁸, Joel Guthridge⁸, S. Louis Bridges, Jr.⁹, Laura Donlin⁹, Susan Goodman⁹, Edward DiCarlo⁹, Vivian Bykerk⁹, Christopher Ritchlin¹⁰, Darren Tabechian¹¹, James Lederer⁴, Ellen Gravallese¹², Mandy McGeachy¹³, Gary S. Firestein¹⁴, Peter Gregersen¹⁵, Diane Horowitz¹⁶, David Boyle¹⁷, Laura Geraldino-Pardilla¹⁸, Harris Perlman¹⁹, Arthur Mandelin²⁰, Joan Bathon¹⁸, Laura Hughes²¹, V. Michael Holers²², Kevin D Deane²³, Larry Moreland²², Andrew Filer²⁴, Costantino Pitzalis²⁵, Lindsy Forbess²⁶, Ami Ben-artzi²⁷, Karen Salomon-Escoto²⁸, Soumya Raychaudhuri⁴, Michael Brenner¹², Accelerating Medicines Partership (AMP) RA/SLE Network²⁹, Andrew McDavid², Jennifer Anolik³ and Deepak Rao⁴, ¹Harvard University, Boston, MA, ²University of Rochester, Rochester, NY, ³University of Rochester Medical center, Rochester, NY, ⁴Brigham and Women's Hospital, Boston, MA, ⁵University of Colorado, Aurora, CO, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Stanford University School of Medicine, Palo Alto, CA, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹¹URMC, Rochester, NY, ¹²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹³University of Pittsburgh, Pittsburgh, PA, ¹⁴University of California, San Diego, San Diego, CA, ¹⁵The Feinstein Inst for Med Research, Larchmont, NY, ¹⁶Northwell Health, Jericho, NY, ¹⁷UCSD, La Jolla, CA, ¹⁸Columbia University, New York, NY, ¹⁹Northwestern University, Chicago, IL, ²⁰Northwestern University Feinberg School of Medicine, Chicago, IL, ²¹University of Alabama at Birmingham, Birmingham, AL, ²²University of Colorado, Denver, CO, ²³University of Colorado Denver Anschutz Medical Campus, Denver, CO, ²⁴University of Birmingham, Birmingham, United Kingdom, ²⁵Queen Mary University of London, London, United Kingdom, ²⁶Cedars-Sinai Medical Center, Los Angeles, CA, ²⁷Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ²⁸University of Massachusetts Medical School, Worcester, MA, ²⁹National Institutes of Health, Washington, DC
Background/Purpose: In rheumatoid arthritis (RA), T cells represent a large proportion of the immune population present in inflamed joint synovium, and subsets of both CD4+…
Abstract Number: 1771 • ACR Convergence 2022
The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
Yanjie Hao¹, Shereen Oon² and Mandana Nikpour³, ¹The University of Melbourne, Melbourne, Australia, ²The University of Melbourne Department of Medicine at St. Vincent’s Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: The concept of treat-to-target (T2T), a strategy in which treatment is directed to reach and maintain a defined goal such as remission or low…
Abstract Number: 1960 • ACR Convergence 2022
Impact of Delaying Initiation of Methotrexate by One Month on the Outcome of RA at One Year
Theresa Than¹, Emmanuelle Dernis², Olivier BROCQ³, Bruno Fautrel⁴, Helena HUGUET⁵, Liana Euller-Ziegler⁶, Lindsay BUSTAMENTE-CENCI⁶, Olivier Vittecoq⁷, Marie-christine PICOT⁵, Cédric Lukas⁸, Claire DAIEN⁹, Charlotte Hua¹⁰, Marlène Genty⁵, Helene Che⁵, Anouck REMY-MOULARD¹¹, Frederic LIOTE¹², Martin Soubrier¹³, Cécile GAUJOUX-VIALA¹⁴, Arnaud Constantin¹⁵, Alain Saraux¹⁶, Emilie Ducourau¹⁷, Stephanie RIST¹⁸, CARINE SALLIOT¹⁹, Nada IBRAHIM-NASSER¹⁸, Clara qUINTEN¹⁸, Vincent Goeb²⁰ and Jacques Morel¹, ¹University and CHU Montpellier, Montpellier, France, ²LE MANS general hospital, LE MANS, France, ³Centre hospitalier Princesse-Grace, Monaco, France, ⁴Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ⁵CHU Montpellier, Montpellier, France, ⁶CHRU Nice, Nice, France, ⁷CHU de Rouen, ROUEN, France, ⁸University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ⁹University Hospital, Saint-Gély-du-Fesc, France, ¹⁰La Lettre du Rhumatologue, Paris, France, ¹¹CHU Montpellier, Montpellier, Chad, ¹²University of Paris, Paris, France, ¹³Gabriel-Montpied Hospital, Clermont-Ferrand, France, ¹⁴CHU Nîmes, Univ Montpellier (IDESP), Nîmes, France, ¹⁵Toulouse University Hospital, Toulouse, France, ¹⁶CHU Brest, Brest, France, ¹⁷CH Orleans, Chambray Les Tours, France, ¹⁸CH orleans, Orleans, France, ¹⁹CHR orleans, Orleans, France, ²⁰CHU Amiens, Amiens, France
Background/Purpose: It is recommended that vaccinations should be performed prior to start methotrexate (MTX) knowing that delaying initiation of background therapy may have an impact…
Abstract Number: 1978 • ACR Convergence 2022
Using Administrative Health Data to Construct a Frailty Index as a Measure of Susceptibility to Adverse Health Outcomes Among Individuals with Rheumatoid Arthritis
Alexandra Legge¹ and Diane Lacaille², ¹Arthritis Research Canada, Dalhousie University, Halifax, NS, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Frailty is increasingly recognized among individuals living with RA. While several tools are available to assess frailty in clinical settings, it is less readily…
Abstract Number: 0019 • ACR Convergence 2021
Increased Circulating CD39+FoxP3+CD4+ Treg Cells in Early Rheumatoid Arthritis Facilitate the Antiinflammatory Action of Methotrexate
Laura Nuño¹, Alejandro Villalba¹, Marta Novella-Navarro², Irene Monjo¹, Diana Peitado¹, Sara Garcia-Carazo¹, Alejandro Balsa² and Maria-Eugenia Miranda-Carus¹, ¹Hospital La Paz - IdiPAZ, Madrid, Spain, ²Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: Inhibition of AICAR transformylase by MTX results in augmented release of adenine nucleotides to the extracellular space; these are rapidly hydrolysed by ectonucleotidases CD39…
Abstract Number: 0036 • ACR Convergence 2021
The NAD+ Metabolism Is Altered in Rheumatoid Arthritis and Its Modulation with NAD+ Boosters Exhibits Key Anti-Inflammatory and Anti-Oxidant Effects
Carlos Pérez-Sánchez¹, Luz Marina Sanchez-Mendoza², Nuria Barbarroja³, M.Carmen Abalos-Aguilera⁴, Maria Luque-Tevar⁵, Alejandra Patiño-Trives⁵, Iván Arias de la Rosa³, Cristobal Román-Rodriguez⁶, Juan Antonio Moreno², Maria Isabel Buron², Jose Antonio Gonzalez-Reyes², Marta Rojas-Gimenez⁴, Eduardo Collantes-Estevez⁶, alejandro Escudero⁶, Jose Manuel Villalba² and Chary lopez-pedrera⁶, ¹IMIBIC, Córdoba, Spain, ²Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain, ³University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁴Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Córdoba, Cordoba, Spain, ⁵Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain
Background/Purpose: NAD+ is a key cofactor and second messenger for multiple cellular processes that exhibits antioxidant, anti-apoptotic, and anti-inflammatory properties. Numerous publications and clinical trials…
Abstract Number: 0103 • ACR Convergence 2021
Patients with Inflammatory Rheumatic Diseases Are at Increased Risk of COVID-19 Related Hospitalization: Data from a Prospective Controlled Cohort Study
Laura Boekel¹, Femke Hooijberg¹, Erik Vogelzang², Maureen Leeuw¹, Sadaf Atiqi¹, Ronald van Vollenhoven³, Alexandre Voskuyl², Irene van der Horst-Bruinsma², Willem Lems¹, Taco Kuijpers², Marieke van Ham⁴, Luuk Wieske², Filip Eftimov², Maurice Steenhuis⁴, Sofie Keijzer⁴, Olvi Christianawati⁴, Floris Loeff⁴, Sander Tas⁵, Mike Nurmohamed⁶, Theo Rispens⁴ and Gertjan Wolbink¹, ¹Reade, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Sanquin, Amsterdam, Netherlands, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands, ⁶Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands
Background/Purpose: Retrospective studies have suggested that patients with rheumatic diseases may be at increased risk of severe COVID-19 related disease, and that this risk may…
Abstract Number: 0178 • ACR Convergence 2021
Abdominal Obesity May Confound Accuracy of Cardiovascular Risk Prediction in Rheumatoid Arthritis; Can Coronary Atherosclerosis Imaging and Biomarkers Help?
George Karpouzas¹, sarah ormseth², Elizabeth Hernandez² and Matthew Budoff³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, ³Division of Cardiology, and the Lundquist Institute ay Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Accurate cardiovascular risk stratification is essential in rheumatoid arthritis (RA) care. Previous studies evaluated the impact of obesity (defined as body mass index) on…
Abstract Number: 0275 • ACR Convergence 2021
Impact of Disease Activity on Left Ventricular Diastolic Dysfunction in Rheumatoid Arthritis Patients
Natalia Guajardo-Jauregui, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Alejandra Rodriguez-Romero, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Catalina Andrade-Vazquez and Alan De Leon-Yañez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Cardiovascular disease (CVD) is the main cause of mortality in patients with rheumatoid arthritis (RA) reflected by a higher prevalence of cardiovascular risk factors…
Abstract Number: 0293 • ACR Convergence 2021
Increased Prevalence of Scleroderma Specific Autoantibodies in Seropositive Rheumatoid Arthritis with Lung Involvement
Vasiliki Koulouri¹, Kyriaki Tavernaraki², Mayra Giannelou³ and Clio Mavragani¹, ¹National and Kapodistrian University of Athens, Athens, Greece, ²Imaging and Interventional Radiology, Sotiria General and Chest Diseases Hospital, Athens, Greece, ³Department of Rheumatology, General Hospital of Athens "G. Gennimatas", Athens, Greece
Background/Purpose: To evaluate the prevalence of scleroderma (SSc) specific and anti-Ro52 autoantibodies in seropositive rheumatoid arthritis (RA) patients with lung involvement.Methods: Sera from 67 seropositive…
Abstract Number: 0494 • ACR Convergence 2021
The Distribution of Social Deprivation, Distance to Care and Disease Burden in Rheumatoid Arthritis Patients in the United States
Sharon Dowell¹, Huifeng Yun², Jeffrey Curtis³, Lang Chen⁴, Manuela Pedra-Nobre⁵, Dianne Wollaston⁶, SAWSAN NAJMEY⁷, Cynthia Lawrence-Elliott⁸, Theresa Lawrence-Ford⁹, Heather North¹⁰, Robin Dore¹¹, Soha Dolatabadi¹², Thaila Ramanujam¹³, Anne Winkler¹⁴, Stacy Kennedy¹⁵, Stephanie Ott¹⁶, Stephanie Ledbetter¹⁷, Grace Wright¹⁸ and Gail Kerr¹⁹, ¹Howard University College of Medicine, Washington, DC, ²University of Alabama Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama, Birmingham, AL, ⁵North Jersey Rheum. Center, Westfield, NJ, ⁶Memorial Advanced Rheumatology, Houston, TX, ⁷Midstate Rheumatology Center, PA, Freehold, NJ, ⁸North Georgia Rheum Group, Atlanta, GA, ⁹North Georgia Rheum Group, Atlanta, MD, ¹⁰Pardee UNC, Hendersonville, NC, ¹¹Robin K. Dore, MD Inc, Tustin, CA, ¹²Soha Dolatabadi, MD, Los Angeles, CA, ¹³Santa Cruz Rheumatology, Inc., Santa Cruz, CA, ¹⁴Winkler Medical Practice, Springfield, MO, ¹⁵Rowan Diagnostic Clinic, Concord, NC, ¹⁶Fairfield Medical Center, Carroll, OH, ¹⁷University of Alabama at Birmingham, Birmingham, AL, ¹⁸Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, ¹⁹Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC
Background/Purpose: The overall success of RA therapy is dependent on access to specialty care, insurance coverage and effective management of associated comorbidities. Whether RA disease…
Abstract Number: 0574 • ACR Convergence 2021
Prevalence and Early Progression of Lung Diseases in Patients with Recently-Diagnosed Rheumatoid Arthritis: A Prospective Cohort Study
Tina Mahajan¹, Daniel Hershberger¹, Matt Devries², Punyasha Roul¹, Yangyuna Yang¹, Sherrie Edwards¹, Geoffrey Thiele¹, Ted Mikuls¹, James O'Dell¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha
Background/Purpose: Several types of lung diseases complicate the rheumatoid arthritis (RA) disease course such as interstitial lung disease (ILD) and obstructive lung diseases. The prevalence…
Abstract Number: 0605 • ACR Convergence 2021
Impact of Area of Residence on Perceptions of Health and Disease Activity in Ethnic Minorities with Rheumatoid Arthritis in an Urban Setting
Mohamed Jalloh¹, Sharon Dowell², Richard Ogunti¹ and Gail Kerr³, ¹Howard University Internal Medicine Residency, Washington, DC, ²Howard University College of Medicine, Washington, DC, ³Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Health care disparities in hypertension and other chronic disease are well established. Ethnic minority residents of Washington DC, particularly Wards 7 and 8, have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].